Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047127 | 0.84 | GABRA1 (0.42) | CCR1GABRA1GABRG2GABRB3IRAK4 | |
| SCHEMBL20416692 | 0.82 | CCR1 (0.39) | CCR1GABRA1GABRG2GABRB3IRAK4 | |
| SCHEMBL19085083 | 0.82 | CCR1 (0.39) | CCR1GABRA1GABRG2GABRB3IRAK4 | |
| SCHEMBL20400486 | 0.81 | CCR1 (0.38) | CCR1GABRA1GABRG2GABRB3IRAK4 | |
| SCHEMBL2936127 | 0.81 | IRAK4 (0.44) | CCR1IRAK4 | |
| SCHEMBL29337105 | 0.81 | IRAK4 (0.44) | CCR1IRAK4 | |
| SCHEMBL20436438 | 0.79 | TSHR (0.37) | CCR1GABRA1GABRG2GABRB3IRAK4 | |
| SCHEMBL20416689 | 0.78 | CCR1 (0.35) | CCR1GABRA1GABRG2GABRB3IRAK4 | |
| SCHEMBL17349929 | 0.78 | CCR1 (0.35) | CCR1GABRA1GABRG2GABRB3IRAK4 | |
| SCHEMBL20442132 | 0.78 | CCR1 (0.35) | CCR1GABRA1GABRG2GABRB3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | CCR1 838/4885GABRA1 2882/4885GABRG2 3768/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | CCR1 836/4885GABRA1 2848/4885GABRG2 3759/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | CCR1 838/4885GABRA1 2882/4885GABRG2 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.